Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis

Introduction.- Evidence for an Early Treatment of Multiple Sclerosis.- Inflammation, Demyelination, and Axonal Degeneraton: Three Aspects of the Pathogenesis of Multiple Sclerosis Revealed by Campath-1H Treatment.- Genetic Regulation of Nerve Cell Death/Glial Activaion and Protective Effects of Myelin Basic Protein Autoimmune Neurotrophin Production in Mechanically Induced Neurodegeneration.- Neuroprotective Treatment in Primary Progressive Multiple Sclerosis: Phase I/II Study with Riluzole.- Neuropathology and Disease Progression in Multiple Sclerosis.- Autoimmune Inflammation and Multiple Sclerosis.- Early Treatment of Progression in Multiple Sclerosis.- Imaging for Tissue Characterization in Multiple Sclerosis and Other White Matter Diseases.- Monounsaturated Fatty Acids and Neuroprotection. The Results of a Study of Cognitive Decline in Old Age. Is There a Case for this Treatment in Multiple Sclerosis?.- Neuroprotection in Acute Ischemic Stroke: Lessons for Early Treatment inMultiple Sclerosis.- Soluble VCAM-1 Release Indicates Inflammatory Blood-Brain Barrier Pathology and Further Modulates Adhesion.- Early Treatment in Multiple Sclerosis with Intravenous Immunoglobulin: Rationale and Study Design.- Serial Magnetic Resonance Imaging in Patients with a First Clinical Episode Suggestive of Multiple Sclerosis: Outline of a Research Protocol.- T1-Hypointense Lesions (T1 Black Holes) in Mild-to-Moderate Disability Relapsing Multiple Sclerosis.- Acute Monosymptomatic Optic Neuritis: Potential Clues to Early Therapy in Multiple Sclerosis.- Antibody Mediated Demyelination.- Anti-MOG Antibodies as Early Predictors for Conversion to Relapsing-Remitting Disease Course in Patients Suggestive of Multiple Sclerosis.- Sunlight, Vitamin D, and Multiple Sclerosis.- The Yin and Yang of Inflammation in Multiple Sclerosis.- Management of Interferon-b1b Failures in Multiple Sclerosis with Interferon-an3.